Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
- 1.7k Downloads
Alectinib (Alecensa®) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan drug designation. Approval was based on a phase 1–2 study in ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC who received twice-daily alectinib 300 mg. In the phase 2 portion, 93.5 % of patients achieved an objective response. Treatment response was rapid, with a partial response achieved in two-thirds of patients within 3 weeks (cycle 1). Patient follow-up is ongoing, and after approximately 2 years, 19.6 % of patients had achieved a complete response, and the 2-year progression-free survival rate is 76 %. During treatment with alectinib (median follow-up approximately 8 months), there was no progression of CNS lesions among patients with known CNS metastases at baseline (although prior radiation therapy may have confounded results). In preclinical models, alectinib was active against most ALK fusion-gene mutations related to crizotinib resistance, and preliminary results from clinical trials indicate efficacy in crizotinib-refractory NSCLC. Alectinib was generally well tolerated in clinical trials, and there were no treatment-related grade 4 adverse events or deaths. The most common grade 3 treatment-related adverse events were decreased neutrophil counts and increased creatinine phosphokinase. While more data are needed to confirm the efficacy of alectinib and to evaluate its activity in crizotinib-resistant disease, the drug provides a very promising option for the treatment of ALK-rearranged advanced NSCLC.
KeywordsEpidermal Growth Factor Receptor Objective Response Rate Epidermal Growth Factor Receptor Mutation Anaplastic Lymphoma Kinase Anaplastic Large Cell Lymphoma
The preparation of this review was not supported by any external funding. Kate McKeage is salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
- 1.American Cancer Society. Cancer facts and figures 2014 [online]. http://www.cancer.org/acs. Accessed 2014 Aug 12.
- 10.Chugai Pharmaceutical Co Ltd. Alecensa® (alectinib): Japanese prescribing information. Tokyo: Chugai Pharmaceutical Co Ltd; 2014.Google Scholar
- 16.Ou S-HI, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9:549–53.CrossRefGoogle Scholar
- 19.Nakagawa K, Hida T, Seto T, et al. Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study [abstract no. 8103 plus poster]. J Clin Oncol. 2014;32(5 Suppl).Google Scholar
- 20.Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15:1119–28.PubMedCrossRefGoogle Scholar
- 21.Ou S, Gadgeel S, Chiappori A, et al. Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028) [abstract]. Eur J Cancer. 2013;49:S19.Google Scholar
- 22.Tamura T, Seto T, Nakagawa K, et al. Updated data of a phase I/II study (AF-001JP) of alectinib, a CNS-penetrant, highly selective ALK inhibitor in ALK-rearranged advanced NSCLC [abstract no. 10]. In: Multidisciplinary Symposium in Thoracic Oncology, Chicago (IL); Oct 30–Nov 1 2014.Google Scholar
- 23.Seto T, Hida T, Nakagawa K, et al. Anti-tumour activity in crizotinib pre-treated ALK-rearranged NSCLC in JP28927 study [abstract no. 1224O]. In: European Society for Medical Oncology. Madrid; Sep 2014. p. 26–30.Google Scholar